We aimed to investigate cardiovascular disease (CVD) risk and risk factors and evaluate the relationship among disease activity, inflammation markers, and uric acid levels in patients with rheumatoid arthritis (RA) and spondyloarthritis (SpA).
INTRODUCTION
Spondyloarthritis (SpA) and rheumatoid arthritis (RA) are chronic inflammatory damaging diseases with specific characteristics. Several studies have indicated higher cardiovascular disease (CVD) risk and mortality rates among these patients compared to the general population (1, 2) . Cardiovascular involvement has been demonstrated as the most important cause of mortality in both of the diseases (3, 4) . It is considered that systemic inflammation, circulating proinflammatory cytokines, and traditional risk factors may be effective on accelerated atherosclerosis, hypertension, dyslipidemia, obesity, and insulin resistance (2, 5) .
Low high-density lipoprotein cholesterol (HDL-C), high triglycerides (TG), hypertension, abdominal obesity, and insulin resistance describe a group of risk factors for CVD and comprise the metabolic syndrome (MetS). Higher MetS frequency has been reported in patients with RA and ankylosing spondylitis (AS) compared to the general population (2, 5) .
In recent years, while examining the new biomarkers pointing to the CVD risk, it has been argued that serum uric acid levels can be a potent component for vascular events in RA; likewise, hyperuricemia may be correlated to MetS in general population (6) (7) (8) (9) . There are a limited number of studies that investigated the association between uric acid and cardiovascular risk in patients with RA (8, 9) . On the other hand, to the best of our knowledge, the relationship among uric acid, cardiovascular risk, and inflammatory markers has not been reported in patients with SpA. tients with SpA fulfilling the 2010 Assessment of SpondyloArthritis international Society axial spondyloarthritis classification criteria, and 95 healthy controls without any inflammatory disease were included. Written informed consents of all participants were received. The ethics committee of Ankara Numune Training and Research Hospital approved this protocol (Approval date/number: 02/19/2015/E-15-420). Exclusion criteria were (a) <18 years old, (b) patients with an active infection, cancer, or thyroid dysfunction, and (c) pregnant patients.
Demographic features, disease diagnosis, and medications of individuals (steroids, nonsteroidal anti-inflammatory drugs [NSAIDs], synthetic and biological disease-modifying antirheumatic drugs [DMARDs], and drugs for diabetes, hypertension, and hyperlipidemia) were recorded. History of smoking, habitual drinking, and comorbid diseases including diabetes mellitus, hypertension, and dyslipidemia were assessed. Body weight and height, waist circumference, and blood pressure of the participants were determined by the same physician. The laboratory measures including values of plasma glucose, serum lipids (total cholesterol, low-density lipoprotein [LDL], HDL, TG), uric acid, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) were obtained. Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (aCCP) were also noted for patients with RA. Body mass indexes (BMI) of the individuals were calculated in kg/m 2 . Individuals whose BMI values are >30 kg/m 2 were specified as obese.
Tender and swollen joint count, morning stiffness, pain, and patients' global assessments using a visual analog scale (VAS, 0-10 cm) were recorded in patients with RA and SpA. Disease activity score 28 (DAS 28), Ankylosing Spondylitis Disease Activity Score (ASDAS), and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) were calculated. Remission, low, moderate, and high disease activities were identified according to DAS 28 results for patients with RA (≤2.6, 2.7-3.2, 3.3-5.1, and >5.1, respectively). Scores of BASDAI and ASDAS are calculated in patients with SpA. A BASDAI value of >4 is considered active disease. Inactive, low, high, and very high disease activities were specified according to the ASDAS score (<1.3, 1.3-2.1, 2.2-3.5, and >3.5, respectively) (10) (11) (12) .
National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) criteria were used for identifying MetS. These criteria require at least three of the under-mentioned components for diagnosis:
• high waist circumference >102 cm and >88 cm (for men and women, respectively),
• elevated triglyceride levels (≥150 mg/dl),
• low HDL cholesterol levels (<40 mg/dl in men/<50 mg/dl in women),
• BP ≥130/85 mmHg, and
• fasting plasma glucose ≥110 mg/dl (13) .
Heart age and 10-year CVD risk were evaluated with the Framingham risk score available at "www.framinghamheartstudy.org." Data on age, gender, smoking status, systolic BP, hypertension treatment, diabetes history, HDL, and total cholesterol levels were used to assess risk of developing CVD in the following ten years (14) . Table 4 .
SPSS (Statistical
Patients with RA were divided into two groups according to the Framingham risk score <10% (n=46) and ≥10% (n=52). Uric acid levels were higher in those patients with a Framingham score ≥10% (4.44±1.28, 5.15±1.14 in patients with risk score <10% and ≥10% respectively, p=0.005). A receiver operating characteristic (ROC) curve was drawn for uric acid to detect an increase in cardiovascular risk by more than 10% (Fig. 1) . ROC was performed for uric acid (n=46 and n=52 patients with Framingham risk <10% and ≥10%, respectively). The area under the curve for uric acid was 0.693±0.05 (0.58-0.80 CI 95%, p=0.001). The sensitivity (probability that a patient with >10% Framingham risk score had UA level over a determined cutoff) and specificity (probability that a patient with <10% Framingham risk score had UA level below that cutoff) of UA were calculated for a cutoff level. The best Youden index was 0.38 and a cutoff value of UA 5.05 mg/dL proved 58% sensitivity and 80% specificity.
DISCUSSION
In the current study, the aim was to explore CVD risk factors and MetS existence in patients with RA and SpA and to appraise the relationship among CVD risk, laboratory markers, and disease activity. Our findings suggest that cardiovascular risk was similar in control and patient groups; however, the Framingham risk score was associated with uric acid and RF levels in patients with RA.
Studies reported increased CVD risk and mortality in patients with RA and AS (15, 16) . For CVD risk management, European League Against Rheumatism endorses that CVD risk should be assessed every 5 years in patients with RA, AS, and psoriatic arthritis (17) . Agarwal et al. (15) indicated that various CVD risk factors were worse in RA although a 10-year CVD risk with Framingham score was similar between the patients with RA and control groups. In the same way, in a study with patients with AS, the CVD risk score was found to be similar to the control group (2) . In this study, similar CVD risk percentages were obtained in patient and control groups as in other studies. On the other hand, when individual cardiovascular risk factors were analyzed, it was noted that BMI, waist circumference, and BP patterns were higher in patients with RA. Previous studies showed that a great number of patients with RA with low or moderate cardiovascular risk scores had carotid atherosclerosis on ultrasound (18) (19) (20) . Therefore, patients who do not have high CVD risk scores may have greater risk than we predict and they may benefit from different methods of evaluation for CVD risk. Metabolic syndrome is framed by classical cardiovascular risk factors. The prevalence of MetS in the literature ranges between 10.5% and 53.8% in the general population, between 20% and 50% in patients with RA, and between 11% and 45.8% in patients with AS. MetS prevalence is reported to be higher in groups with the inflammatory disease, whereas there are studies presenting similar prevalence with the normal population (1) (2) (3) (4) (5) (21) (22) (23) (24) (25) (26) . MetS frequency in this study was 35.8% in healthy controls; 43.9% in the RA group, and 41.5% in patients with SpA, and there was no difference between the groups. It has been reported that the frequency of MetS may vary according to geographical and ethnic characteristics, and it is higher in the United States than in Asian countries (5) . Although it was argued that inflammatory arthritis may increase the risk of MetS with various pathways, conflicting results can be obtained due to the inhibition of the cytokine pathway by the DMARDs' therapies and heterogeneous parameters, such as demographic variables (age and gender distribution), disease activity, and duration in different studies.
Outcomes from studies investigating the relationship among disease activity, CVD risk, and MetS in patients with RA and AS are variable. There are studies that found higher DAS 28 values in patients with RA with MetS (4, 23, 25, 27) while there are also studies advocating that there is no difference between the two groups (24, 26) . Similarly, studies in patients with AS suggest that disease activity can be higher in patients with MetS or there can be no association between disease activity and MetS (1, 2) . Although the relationship between disease activity scores and MetS may be varied, blood inflammation signs (ESR and CRP) were found to be unrelated to MetS in many studies (1, 2, 4, (23) (24) (25) (26) . In our patient groups, DAS 28, ASDAS, BASDAI, ESR, CRP, and VAS pain values were not found to be associated with MetS. Only ESR value from these variables was found to be correlated with the Framingham risk score, but it was observed that ESR had no significant effect on the increase of CVD risk in the regression analysis.
There is developing evidence that uric acid levels can have a role in CVD risk. In several studies, hyperuricemia was associated with insulin resistance, hypertension, coronary artery disease risk, and obesity (6, 8, 9, 28, 29) . Authors advocated that uric acid might promote endothelial dysfunction and increase platelet adhesiveness. Hannavi et al. (30) showed a significant association between carotid intima-media thickness and uric acid levels; they suggest that systemic inflammation and hyperuricemia may interact synergistically to stimulate increased atherogenesis. Uric acid, associated with traditional cardiovascular risk factors, was examined with a limited number of studies in patients with RA. Although Kuo et al. (8) determined no difference in the rate of hyperuricemia among patients with RA and control group, hyperuricemia seemed to be more strongly associated with peripheral arterial events among the patients with RA. Chavan et al. (9) studied various biochemical parameters as CVD risk components in RA and they observed that increased uric acid levels may play a part for CVD. Uric acid is thought to be a functionally active molecule that can support proatherogenic processes including oxidative stress extensive inflammation, and endothelial dysfunction (8) . In our study, uric acid levels were not different in RA, SpA, and control groups; however, we found a significant correlation between Framingham risk score and uric acid only in patients with RA. We detected that CVD risk was associated with uric acid and age in patients with RA, whereas CVD risk was only associated with age in patients with SpA. The ROC curve indicated that uric acid might be a predictor for increase in cardiovascular risk by more than 10%. On the other hand, low sensitivity and low Youden index result have also shown that the cutoff value of UA (5.05) is not useful enough to detect the patients with more than 10% risk of CVD. Outcomes of this study corroborate that the serum uric acid level may increase cardiovascular risk with a different pathway and may be an independent marker of cardiovascular risk in RA. Widespread inflammation and vascular damage in RA are well known and it is possible that uric acid will worsen and accelerate this progression. On the other hand, SpA seems to be more innocent than RA in terms of cardiovascular risk.
Relatively small and younger patient population in the SpA group was thought to be the limitation of our study. Additionally, longitudinal studies in larger samples are required to support our preliminary results and understand the impact of uric acid on cardiovascular risk in patients with SpA.
CONCLUSION
In the present study, CVD risk scores of patients with RA and SpA were similar to those of the general population. The uric acid level was found to be associated with the 10-year CVD risk in patients with RA and this parameter may play a role with a different pathway as a predictor for increase in cardiovascular risk by more than 10% in patients with RA. 
